Acellbia® and Mabtera® are recognize CD20-positive cells with equal efficiency
https://doi.org/10.17650/1818-8346-2015-10-4-56-59
Abstract
In present study were compared characteristics of rituximab produced by Hoffmann–La Roche (Mabtera®) and first domestic biosimilar Acellbia® from Biocad Company. Concentration of protein was measured using Bradford, s method. According to our results, protein concentration in formulations was the same. We electrophoresed formulations in denaturing conditions. Protein from formulations was denatured into fragments. Heavy and light chains of immunoglobulin were observed in gel. Finally, we performed flow cytometry where rituximab was used as primary antibody to detect CD20-positive B-cells of patients with B-cell chronic lymphocytic leukemia. Both Mabtera® and Acellbia® recognized the same number of cells. Thus, assays performed in vitro submitted identity of Mabtera® and Acellbia® characteristics.
About the Authors
V. A. Misyurin
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia;
“GenoTechnology” LLC
Russian Federation
Russian Federation
24 Kashirskoye Shosse, Moscow, 115478;
104 Profsoyuznaya St., Moscow, 117485
A. V. Misyurin
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia;
“GenoTechnology” LLC
Russian Federation
Russian Federation
24 Kashirskoye Shosse, Moscow, 115478;
104 Profsoyuznaya St., Moscow, 117485
A. E. Misyurina
“GenoTechnology” LLC;
Hematology Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
104 Profsoyuznaya St., Moscow, 117485;
4a Novyy Zykovskiy Proezd, Moscow, 125167
Yu. P. Finashutina
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia;
“GenoTechnology” LLC
Russian Federation
Russian Federation
24 Kashirskoye Shosse, Moscow, 115478;
104 Profsoyuznaya St., Moscow, 117485
M. A. Baryshnikovа
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
24 Kashirskoye Shosse, Moscow, 115478
Russian Federation
24 Kashirskoye Shosse, Moscow, 115478
O. S. Burova
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
24 Kashirskoye Shosse, Moscow, 115478
Russian Federation
24 Kashirskoye Shosse, Moscow, 115478
S. K. Kravchenko
Hematology Research Center, Ministry of Health of Russia
Russian Federation
4a Novyy Zykovskiy Proezd, Moscow, 125167
Russian Federation
4a Novyy Zykovskiy Proezd, Moscow, 125167
References
1. Marcus R., Imrie K., Belch A. et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105(4):1417–23.
2. Salles G., Mounier N., de Guibert S. et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELAGOELAMS FL2000 study. Blood 2008;112(13):4824–31.
3. http://www.google.com/patents/US57361374. http://www.drugbank.ca/drugs/DB00073
4. Nebija D., Kopelent-Frank H., Urban E. et al. Comparison of two-dimensional gel electrophoresis patterns and MALDI-TOF MS analysis of therapeutic recombinant monoclonal antibodies trastuzumab and rituximab. J Pharm Biomed Anal 2011;56(4):684–91.
5. Алексеев С.М., Капланов К.Д., Иванов Р.А., Черняева Е.В. Современный подход к разработке и исследованию биоаналогов на примере первого российского препарата моноклональных антител – Ацеллбия® (Ритуксимаб). Исследования и практика в медицине 2015;1(2):8–12. [Alekseev S.M., Kaplanov K.D., Ivanov R.A., Chernyaeva E.V. The modern approach to the development and study of biosimilars on the example of Russian first monoclonal antibody preparations – Atsellbiya® (Rituximab). Issledovaniya i praktika v meditsine = Research and Practice in Medicine 2015;1(2):8–12. (In Russ.)].
6. Капланов К.Д., Зарицкий А.Ю., Алексеев С.М. и др. Начало эры применения биоаналогов моноклональных антител в онкологии: современные международные рекомендации и результаты исследования первого российского биоаналога ритуксимаба у больных В-клеточной неходжкинской лимфомой. Современная онкология 2014;16(2): 38–44. [Kaplanov K.D., Zaritskiy A.Yu., Alekseev S.M. et al. The era of monoclonal antibodies biosimilars application in oncology: current international recommendations; results of the first Russian rituximab biosimilar study in patients with B-cell non-Hodgkin,s lymphoma. Sovremennaya onkologiya = Modern Oncology 2014;16(2):38–44. (In Russ.)].
Review
For citations:
Misyurin V.A., Misyurin A.V., Misyurina A.E., Finashutina Yu.P., Baryshnikovа M.A., Burova O.S., Kravchenko S.K. Acellbia® and Mabtera® are recognize CD20-positive cells with equal efficiency. Oncohematology. 2015;10(4):56-59. (In Russ.) https://doi.org/10.17650/1818-8346-2015-10-4-56-59
Views:
11736
Email this article 